In this interview, Technology Networks spoke with Dr. Sophie Mayle, Dr. Paul Royle and Dr. John Cardone from Bio-Rad's ...

Request To Download Free Sample of This Strategic Report @ Catalysts of Market Growth: The buoyant growth trajectory of the global monoclonal antibodies market is propelled by a convergence of ...

today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists ...

NextCure, Inc. has announced that it has dosed its first patient in a Phase 1 clinical trial for LNCB74, an antibody-drug conjugate targeting B7-H4 for the treatment of multiple cancers.

today announced findings on the prolonged benefits of its nasal anti-CD3 monoclonal antibody in sustaining tissue homeostasis and mitigating the side effects associated with GLP-1 agonists ...

Ltd. The partnership will leverage MediLink's TMALIN antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC, known as ZL-6201, which includes an antibody discovered by Zai Lab.

(“MediLink”) to use MediLink’s TMALIN ® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC ... Additionally, LRRC15 is upregulated in cancer-associated fibroblasts (CAFs) ...

a biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders ... the success of ADCs to develop autoimmune treatments using its novel drug ...

Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit www.lifordi.com. BURLINGTON, MA - January 9, 2024 -- Lifordi Immunotherapeutics, ...